PH Tech

Transaction

Published on: 25-09-2023

Sector: Health & Tech
Business: Tissue and Cellular Engineering
Type of transaction: Fundraising
Year of transaction: 2022
Company website: www.meccellis.com

THE COMPANY

PH Tech, which owns Meccellis Biotech and Apha Biomat, stands out in the French healthtech landscape for its expertise in tissue and cell engineering. Specialized in the development, design, manufacture and distribution of biological implants, PH Tech meets the challenges of gastrointestinal, mammary and dental surgery. With a commercial presence in more than 20 countries and a decade of experience, PH Tech is an example of French excellence in the medical sector, offering innovative solutions for the treatment of complex pathologies.

THE TRANSACTION

PH Tech launches the Xenopha project, an innovation that combines biological tissue and biopolymer to create 3D implants, particularly for breast reconstruction. With this round of financing, PH Tech is preparing to industrialize Xenopha and expand into new markets.

The deal was backed by investors Volney Développement, Naco, Synergence and Océan Participations, the latter of which increased its stake. Ama Partners played a key role in advising PH Tech throughout the fundraising process, facilitating investor contacts and negotiations, underscoring the importance of expert support in securing financing and sustaining PH Tech's growth.

The significant investments and institutional support received testify to the confidence placed in PH Tech and its disruptive potential in the medical field. The partnership with investment funds and regional banks and the renewed confidence of Océan Participations underline the importance of PH Tech in the innovation and healthcare landscape.

TESTIMONY

« A funding round is usually complex. Add a pandemic period and the operation becomes a showdown. Alienor has been able to accompany our group in our development phase by being a force of proposals and providing constant support throughout the process. »